These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12757175)

  • 1. Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.
    Thuluvath PJ; Pande H; Maygers J
    Dig Dis Sci; 2003 Mar; 48(3):594-7. PubMed ID: 12757175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
    Thuluvath PJ; Maheshwari A; Mehdi J; Fairbanks KD; Wu LL; Gelrud LG; Ryan MJ; Anania FA; Lobis IF; Black M
    Gut; 2004 Jan; 53(1):130-5. PubMed ID: 14684587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.
    Younossi ZM; Mullen KD; Hodnick S; Barnes DS; Carey WD; McCullough AC; Easley K; Gramlich T; Liebermann BY
    J Clin Gastroenterol; 2003; 36(5):427-30. PubMed ID: 12702987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
    Bizollon T; Adham M; Pradat P; Chevallier M; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Transplantation; 2005 Feb; 79(3):325-9. PubMed ID: 15699763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)].
    Olveira A; Serrano C; Erdozain JC; Calleja JL; Castillo P; Segura JM; Escartín P
    Gastroenterol Hepatol; 2003 Oct; 26(8):465-8. PubMed ID: 14534017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin.
    Carlsson T; Lindahl K; Schvarcz R; Wejstal R; Uhnoo I; Shev S; Reichard O
    J Viral Hepat; 2000 Nov; 7(6):409-13. PubMed ID: 11115051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
    Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
    Engler S; Flechtenmacher C; Wiedemann KH; Gugler R; Stremmel W; Kallinowski B
    J Viral Hepat; 2004 Jan; 11(1):60-8. PubMed ID: 14738559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
    Weegink CJ; Sentjens RE; Beld MG; Dijkgraaf MG; Reesink HW
    J Viral Hepat; 2003 May; 10(3):174-82. PubMed ID: 12753335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
    Brillanti S; Levantesi F; Masi L; Foli M; Bolondi L
    Hepatology; 2000 Sep; 32(3):630-4. PubMed ID: 10960460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
    Zilly M; Lingenauber C; Desch S; Väth T; Klinker H; Langmann P
    Eur J Med Res; 2002 Apr; 7(4):149-54. PubMed ID: 12010649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
    Puoti M; Zanini B; Quinzan GP; Ravasio L; Paraninfo G; Santantonio T; Rollo A; Artioli S; Maggiolo F; Zaltron S; Raise E; Mignani E; Resta F; Verucchi G; Pastore G; Suter F; Carosi G;
    J Hepatol; 2004 Aug; 41(2):312-8. PubMed ID: 15288482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.
    Ullerich H; Avenhaus W; Poremba C; Domschke W; Menzel J
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2107-14. PubMed ID: 12452944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
    Brillanti S; Foli M; Di Tomaso M; Gramantieri L; Masci C; Bolondi L
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):130-4. PubMed ID: 10363198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
    Teuber G; Pascu M; Berg T; Lafrenz M; Pausch J; Kullmann F; Ramadori G; Arnold R; Weidenbach H; Musch E; Junge U; Wiedmann KH; Herrmann E; Zankel M; Zeuzem S
    J Hepatol; 2003 Oct; 39(4):606-13. PubMed ID: 12971972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.